Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
| Revenue (TTM) | $49.19B |
| Gross Profit (TTM) | $35.25B |
| EBITDA | $18.93B |
| Operating Margin | 34.40% |
| Return on Equity | 46.60% |
| Return on Assets | 10.70% |
| Revenue/Share (TTM) | $24.14 |
| Book Value | $10.93 |
| Price-to-Book | 5.60 |
| Price-to-Sales (TTM) | 2.48 |
| EV/Revenue | 3.231 |
| EV/EBITDA | 9.45 |
| Quarterly Earnings Growth (YoY) | 153.10% |
| Quarterly Revenue Growth (YoY) | 5.70% |
| Shares Outstanding | $2.04B |
| Float | $2.04B |
| % Insiders | 0.10% |
| % Institutions | 84.87% |
Volatility is currently expanding
Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff and $43 billion in debt put the pace of future increases on a collision course with the drugs Wall Street is betting everything on.
Four companies kept raising their dividends even as the pandemic hammered their sectors in 2020, and they are still raising today. The question is whether their yields and valuations make them worth buying right now.
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.
Bristol Myers Squibb reports mixed Phase III results for admilparant in IPF, while RYZ101 delivers a significant win in advanced GEP-NETs.
The controversial investor has been weighing in on biopharma stocks even though he's banned from doing so.
Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an experimental cancer treatment raised questions about the market's reaction to the announcement. The US drugmaker reported that its ACTION-1 Phase 3 trial met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival for RYZ101 in patients with advanced gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Bristol Myers shares surge 35.8% as its Growth Portfolio and pipeline progress fuel momentum, but generic competition and valuation warrant caution.
Bristol Myers Squibb maintains a robust portfolio in oncology and hematology with a focus on specialized treatments. Pfizer leverages its global manufacturing and distribution scale to deliver vaccines and primary care medicines worldwide.
Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on BMY and any ticker you trade — then tracks every position and per-strategy win rate.
